A New Jersey federal judge on Tuesday blocked Emcure Pharmaceuticals and Teva Pharmaceuticals from proceeding with generic versions of Sunovion Pharmaceuticals’ bipolar disorder drug Latuda after the parties agreed to enter a final judgment that allows the defendants to appeal a key claims construction ruling.
The permanent injunction bars Emcure and Teva from bringing their generics to market until Jan. 2, 2019, when Sunovion’s patent is set to expire. However, the parties are free to appeal to the U.S. Court of Appeals for the Federal Circuit a Nov. 15 ruling on how a claim in the patent was constructed.
